EDITOR: | April 20th, 2015

Abattis CEO Roadshow

| April 20, 2015 | No Comments
image_pdfimage_print

Abattis-Bioceuticals-200x125-1April 20, 2015 (Source: Marketwired) — Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (OTCQX:ATTBF)(CSE:ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds and patented equipment to medicinal markets in North America, would like to today announced that the Company’s CEO, William Fleming (“Bill”) wants to thank those that he has had the opportunity to meet during the most recent Company roadshow.

On March 25, 2015 Montreal, Quebec Canada, Bill, was asked to present by Paul Benwell & Associates (www.paulbenwell.com) at the prestigious University Club in Montreal, Quebec to an audience of sophisticated investors, investments brokers and advisors, financial institutions and investor relations professionals. Abattis was invited to share its vision on the company’s focused approach to leveraging cannabis in the botanical pharmaceutical market. The presentation had a question period, followed by an extensive time of networking and socializing to market the Abattis brand.

On April 12, 2015 Las Vegas Nevada, Abattis presented at the Growth Capital Expo 2015 at Caesar’s Palace. Bill presented a corporate overview to private equity, independent investors and merchant banking as well as corporate research companies. Abattis presented an overview of its short and long term strategy for product deployment, nutraceutical acquisition and future botanical pharmaceutical drug development. Abattis had one-on-one meetings with prospective capital groups, suppliers and channel partnerships.

The Company appreciates everyone who came out; we will keep you informed as the Company anticipates participating in up coming investment forums throughout Canada and the USA.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD

Bill Fleming, CEO

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.


Raj Shah

Editor:

Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>


Copyright © 2016 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Leave a Reply

Your email address will not be published. Required fields are marked *